Literature DB >> 29501262

cAMP, cGMP and Amyloid β: Three Ideal Partners for Memory Formation.

Roberta Ricciarelli1, Ernesto Fedele2.   

Abstract

cAMP and cGMP are well established second messengers required for long-term potentiation (LTP) and memory formation/consolidation. By contrast, amyloid β (Aβ), mostly known as one of the main culprits for Alzheimer's disease (AD), has received relatively little attention in the context of plasticity and memory. Of note, however, low physiological concentrations of Aβ seem necessary for LTP induction and for memory formation. This should come as no surprise, since hormesis emerged as a central dogma in biology. Additionally, recent evidence indicates that Aβ is one of the downstream effectors for cAMP and cGMP to trigger synaptic plasticity and memory. We argue that these emerging findings depict a new scenario that should change the general view on the amyloidogenic pathway, and that could have significant implications for the understanding of AD and its pharmacological treatment in the future.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; amyloid hypothesis; long-term potentiation

Mesh:

Substances:

Year:  2018        PMID: 29501262     DOI: 10.1016/j.tins.2018.02.001

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  13 in total

1.  In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.

Authors:  Ramsey Najm; Kelly A Zalocusky; Misha Zilberter; Seo Yeon Yoon; Yanxia Hao; Nicole Koutsodendris; Maxine Nelson; Antara Rao; Alice Taubes; Emily A Jones; Yadong Huang
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

Review 2.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

Review 3.  Role of purines in regulation of metabolic reprogramming.

Authors:  Zhenwei Tang; Wenrui Ye; Haotian Chen; Xinwei Kuang; Jia Guo; Minmin Xiang; Cong Peng; Xiang Chen; Hong Liu
Journal:  Purinergic Signal       Date:  2019-09-06       Impact factor: 3.765

4.  Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.

Authors:  Lutz Frölich; Glen Wunderlich; Claus Thamer; Michael Roehrle; Miguel Garcia; Bruno Dubois
Journal:  Alzheimers Res Ther       Date:  2019-02-12       Impact factor: 6.982

Review 5.  Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.

Authors:  Amy J Tibbo; Gonzalo S Tejeda; George S Baillie
Journal:  Biochem Soc Trans       Date:  2019-10-31       Impact factor: 5.407

6.  The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.

Authors:  Hao Wang; Fang-Fang Zhang; Yong Xu; Hua-Rong Fu; Xiao-Dan Wang; Lei Wang; Wei Chen; Xiao-Yan Xu; Yong-Feng Gao; Ji-Guo Zhang; Han-Ting Zhang
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-10       Impact factor: 5.176

Review 7.  Memory Enhancers for Alzheimer's Dementia: Focus on cGMP.

Authors:  Ernesto Fedele; Roberta Ricciarelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

8.  CircRNA-ceRNA Network Revealing the Potential Regulatory Roles of CircRNA in Alzheimer's Disease Involved the cGMP-PKG Signal Pathway.

Authors:  Yuan Zhang; Lili Qian; Yingying Liu; Ying Liu; Wanpeng Yu; Yanfang Zhao
Journal:  Front Mol Neurosci       Date:  2021-05-21       Impact factor: 5.639

9.  Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia.

Authors:  Diana P Benitez; Shenyi Jiang; Jack Wood; Rui Wang; Chloe M Hall; Carlijn Peerboom; Natalie Wong; Katie M Stringer; Karina S Vitanova; Victoria C Smith; Dhaval Joshi; Takashi Saito; Takaomi C Saido; John Hardy; Jörg Hanrieder; Bart De Strooper; Dervis A Salih; Takshashila Tripathi; Frances A Edwards; Damian M Cummings
Journal:  Mol Neurodegener       Date:  2021-07-15       Impact factor: 14.195

10.  Loss of EPAC2 alters dendritic spine morphology and inhibitory synapse density.

Authors:  Kelly A Jones; Michiko Sumiya; Kevin M Woolfrey; Deepak P Srivastava; Peter Penzes
Journal:  Mol Cell Neurosci       Date:  2019-05-04       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.